Total Funding
55
58
Total FundingSeries B raised
Growth Score
-14 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
10125
Sparrow Pharma is a clinical-stage biopharma company developing treatments for T2D with elevated cortisol and related metabolic conditions.
Robert Jacks: President & CEOPast Role: Symbiomix Therapeutics, Co-Founder, President & Chief Financial Officer- David Katz: Founder and CSO
About the Company
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company addressing metabolic dysfunction from excess cortisol. Leveraging underappreciated scientific insights into corticosteroid biology, the company is working to deliver improved outcomes for patients who struggle to control diabetes and related metabolic conditions with current
options. Its lead product, clofutriben, is an oral, small molecule, designed to target the source of active intracellular cortisol in key tissues.
The company was founded in 2013 by David A. Katz and is based in Portland, Oregon, United States.
